During the past decade, Hermelinen Forskning AB conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hermelinen Forskning AB" are "Psoriasis" (2 trials). Many other conditions were trialed in "Hermelinen Forskning AB" in a lesser frequency.

Most popular intervention types in "Hermelinen Forskning AB" are "Drug" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "CP 690,550 10 mg" (1 trials), "CP 690,550 5 mg" (1 trials), "CP-690,550" (1 trials), "Etanercept 50 mg" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hermelinen Forskning AB" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Hermelinen Forskning AB". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Hermelinen Forskning AB, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hermelinen Forskning AB, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".